BeyondSpring Inc. (BYSI)
NASDAQ: BYSI · Real-Time Price · USD
1.700
-0.050 (-2.86%)
Feb 24, 2025, 11:55 AM EST - Market open
BeyondSpring Employees
BeyondSpring had 36 employees as of December 31, 2023. The number of employees decreased by 37 or -50.68% compared to the previous year.
Employees
36
Change (1Y)
-37
Growth (1Y)
-50.68%
Revenue / Employee
$52,111
Profits / Employee
-$432,444
Market Cap
68.51M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
BYSI News
- 27 days ago - BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies - GlobeNewsWire
- 27 days ago - SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors - GlobeNewsWire
- 3 months ago - BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting - GlobeNewsWire
- 5 months ago - BYSI Sees Quick 5.39% Surge Amid Low Trading Volume - GuruFocus
- 5 months ago - BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024 - GlobeNewsWire
- 5 months ago - BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024 - GlobeNewsWire
- 6 months ago - BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin - GlobeNewsWire
- 7 months ago - SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications - GlobeNewsWire